Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double‐blind, randomized placebo‐controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793478312 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793482693 ◽

2013 ◽

Author(s):

Hashim Hashim ◽

Riyad Almousa

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2009.02209.x ◽

2009 ◽

Vol 63 (12) ◽

pp. 1702-1714 ◽

Cited By ~ 38

Author(s):

M. D. Vardy ◽

H. D. Mitcheson ◽

T.-A. Samuels ◽

J. D. Wegenke ◽

S. Forero-Schwanhaeuser ◽

...

Keyword(s):

Overactive Bladder ◽

Patient Reported Outcomes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Symptom Bother ◽

Patient Reported ◽

OnabotulinumtoxinA 100U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Yearbook of Urology ◽

10.1016/j.yuro.2014.03.010 ◽

2014 ◽

Vol 2014 ◽

pp. 65-67

Author(s):

E.S. Rovner

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

An Investigation of Falling, Balance, Ambulation Status and Quality of Life According to Overactive Bladder Symptoms in Parkinson's Disease

Turkiye Klinikleri Journal of Health Sciences ◽

10.5336/healthsci.2019-70682 ◽

2020 ◽

Vol 5 (2) ◽

pp. 244-252

Author(s):

Sevim ACARÖZ CANDAN ◽

Aslıhan ÇATIKER ◽

Tuba Şaziye ÖZCAN

Keyword(s):

Quality Of Life ◽

Parkinson’S Disease ◽

Parkinson's Disease ◽

Overactive Bladder ◽

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793477069 ◽

2013 ◽

Author(s):

Howard Goldman

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms

Urology ◽

10.1016/j.urology.2020.06.063 ◽

2020 ◽

Vol 144 ◽

pp. 99-105

Author(s):

Daniel R. Greenberg ◽

Ericka M. Sohlberg ◽

Chiyuan A. Zhang ◽

Veronica E. Santini ◽

Craig V. Comiter ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Overactive Bladder ◽

Nerve Stimulation ◽

Sacral Nerve Stimulation ◽

Sacral Nerve ◽

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

European Urology ◽

10.1016/j.eururo.2013.04.001 ◽

2013 ◽

Vol 64 (2) ◽

pp. 249-256 ◽

Cited By ~ 216

Author(s):

Christopher Chapple ◽

Karl-Dietrich Sievert ◽

Scott MacDiarmid ◽

Vik Khullar ◽

Piotr Radziszewski ◽

...

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1058963.510919 ◽

2007 ◽

Author(s):

Pascal Derkinderen

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Double Blind ◽

Randomised Controlled

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo